Technology | June 29, 2006

Stent Specifically Designed to Prevent Restenosis


Using a closed-cell design, the CYPHER stent delivers sirolimus, a drug that selectively targets and interrupts proliferating cells early in the cell cycle, halting the development of neointimal hyperplasia while allowing natural healing and normal re-endothelialization. It is available in over-the-wire and rapid exchange delivery systems. It comes in 8, 13, 18, 28 and 30 mm lengths and has radio-opaque markers.


Additional Content

News | Stents Drug Eluting

July 2, 2024 — Biotronik announced the availability of an expanded Maximum Allowed Diameters (MAD) range for the Orsiro ...

Home July 02, 2024
Home
News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
Subscribe Now